ArticleBlood cancer journal2021
Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice.
Open access · goldAbstract readLetter
In one paragraph
Article in Blood cancer journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
5.4field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 43 citations in OpenAlex.
- Asciminib monotherapy in patients with BCR::ABL1 T315I-mutated chronic-phase chronic myeloid leukemia: phase 1 trial final results.Leukemia · 2026Article
- An overview of strategies and challenges adopted to silence BCR-ABL gene by small interfering RNA.Nanomedicine (London, England) · 2025Review
- Real-World Efficacy Profile of Compassionate Use of Asciminib in an Italian, Multi-Resistant Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Patient Population.Hematological oncology · 2025Article
- Molecular response with asciminib 20 mg QD in a patient intolerant to multiple TKIs.Annals of hematology · 2025Article
- Asciminib in the treatment of chronic myeloid leukemia in chronic phase.Future oncology (London, England) · 2025Review
- Asciminib in Advanced-Line Treatment of Chronic Myeloid Leukemia.European journal of haematology · 2025Article
- Therapeutic options for chronic myeloid leukemia following the failure of second-generation tyrosine kinase inhibitor therapy.Frontiers in oncology · 2024Review
- Genetic Landscape of Chronic Myeloid Leukemia and a Novel Targeted Drug for Overcoming Resistance.International journal of molecular sciences · 2023Review
- Article
- Real-world experience with ponatinib therapy in chronic phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial occlusive events.Blood cancer journal · 2023Article
- Management of chronic myeloid leukemia in 2023 - common ground and common sense.Blood cancer journal · 2023Review
- Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors.Cancers · 2023Article
- A case of chronic myelogenous leukemia with the T315I mutation who progressed to myeloid blast phase and was successfully treated with asciminib.Clinical case reports · 2022Article
- Investigating Potential Cardiovascular Toxicity of Two Anti-Leukemia Drugs of Asciminib and Ponatinib in Zebrafish Embryos.International journal of molecular sciences · 2022Article
- Mechanisms of Resistance and Implications for Treatment Strategies in Chronic Myeloid Leukaemia.Cancers · 2022Review
- Transport and metabolism of tyrosine kinase inhibitors associated with chronic myeloid leukemia therapy: a review.Molecular and cellular biochemistry · 2022Review
- Review
- Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia-From Molecular Mechanisms to Clinical Relevance.Cancers · 2021Review
- Gene Transcription as a Therapeutic Target in Leukemia.International journal of molecular sciences · 2021Review
- Asciminib in chronic myeloid leukemia: many questions still remain to be answered.Blood cancer journal · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
34 authors at 20 institutions in 1 country.
Valentín Garcia-GutiérrezHematology, Hospital Universitario Ramón y Cajal. IRYCIS, Madrid, Spain. jvalentingg@gmail.com.ORCID 0000-0003-4752-0815
Alejandro LunaHematology, Hospital Universitario Ramón y Cajal. IRYCIS, Madrid, Spain.ORCID 0000-0003-2201-3091
Juan M Alonso-DominguezHospital Universitario Fundación Jiménez Díaz, Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD), UAM, Madrid, Spain.
Natalia EstradaInstitut Catala d'Oncologia, Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat, Autònoma de Barcelona, Badalona, Spain.
Concepcion BoqueInstitut Catala d'Oncologia - L'Hospitalet de Llobregat, L'Hospitalet de Llobregat, Spain.
Blanca XicoyInstitut Catala d'Oncologia, Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat, Autònoma de Barcelona, Badalona, Spain.
Pilar GiraldoHospital Quiron Zaragoza, Zaragoza, Spain.
Anna AngonaHematology, Institut Catala d'Oncologia, Girona, Spain.
Alberto Alvarez-LarránHematology Department, Hospital Clínic, Barcelona, Spain.
Fermin Sanchez-GuijoHematology Department, IBSAL-Hospital Universitario de Salamanca, CIC and CIBERONC, University of Salamanca, Salamanca, Spain.
María José RamírezHematology Department, Hospital de Jerez de la Frontera, Jerez, Spain.
Elvira MoraHematology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
Patricia VélezHospital Mutua Terrassa, Terrassa, Spain.
Ana RosellHematology, Hospital Virgen de la Victoria, Malaga, Spain.
Mercedes Colorado AraujoHospital U. Marqués de Valdecilla, Servicio de Hematología-Hemoterapia, Santander, Spain.
Beatriz CuevasHematology, Hospital Universitario de Burgos, Burgos, Spain.
Miguel SagüésInstitut Catala d'Oncologia, Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat, Autònoma de Barcelona, Badalona, Spain.
Montserrat CortesHospital General de Granollers, Barcelona, Spain.
Manuel Perez EncinasHospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain.ORCID 0000-0001-9943-4404
Luis Felipe Casado MonteroHospital Virgen de la Salud, Toledo, Madrid, Spain.
Melania Moreno VegaHospital Doctor José Molina Orosa de Lanzarote, Arrecife, Spain.
Luis SerranoHospital General de Castellón, Castellón, Spain.
Valle GomezHospital Universitario La Princesa, Madrid, Spain.
Carmen Garcia-HernandezHospital General de Alicante, Alicante, Spain.
Sunil LakhwaniDepartment of Hematology, Hospital Universitario de Canarias, La Laguna, La Laguna, Spain.
Antonio Paz CollHospital Universitario Puerto Real, Puerto Real, Spain.
Raquel de PazHematology Department, Hospital Universitario La Paz-Idipaz, Madrid, Spain.
Sara Suarez-VarelaHospital de Jerez de la Frontera, Jerez de la Frontera, Spain.
Andrés Fernandez-RuizInstitut Catala d'Oncologia, Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat, Autònoma de Barcelona, Badalona, Spain.
Raul Perez LopezServicio de Hematología, Hospital Universitario Clínico Virgen de la Arrixaca, Murcia, Spain.
Almudena Ortiz-FernándezInstituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Hospital Universitario Ramón y Cajal, Madrid, Spain.
Antonio Jiménez-VelascoHospital Regional Universitario de Málaga, Málaga, Spain.
Juan Luis Steegmann-OlmedillasHospital Universitario La Princesa, Madrid, Spain.
Juan Carlos Hernández-BoludaHospital Clinico de Valencia, Valencia, Spain.
Universitat Autònoma de Barcelona · ESHospital Jerez Puerta del Sur · ESHospital Universitario de La Princesa · ESInstitut Català d'Oncologia · ESInstituto Ramón y Cajal de Investigación Sanitaria · ESComplejo Hospitalario Universitario de Santiago · ESHospital Clínic de Barcelona · ESHospital Clínico Universitario de Valencia · ESHospital Clínico Universitario Virgen de la Victoria · ESHospital Doctor José Molina Orosa · ESHospital General de Granollers · ESHospital General Universitari de Castelló · ESHospital General Universitario de Alicante Doctor Balmis · ESHospital Regional Universitario de Málaga · ESHospital Universitari i Politècnic La Fe · ESHospital Universitario de Burgos · ESHospital Universitario de Canarias · ESHospital Universitario Fundación Jiménez Díaz · ESHospital Universitario La Paz · ESHospital Universitario Puerto Real · ES
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdultAgedAged, 80 and overFemaleFusion Proteins, bcr-ablHumansLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMaleMiddle AgedNiacinamideProtein Kinase InhibitorsPyrazolesTreatment OutcomeYoung AdultasciminibBCR-ABL1 fusion protein, humanFusion Proteins, bcr-ablNiacinamideProtein Kinase InhibitorsPyrazoles
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.